{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:47:40Z","timestamp":1769604460690,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s13300-019-00699-8","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:01:11Z","timestamp":1572001271000},"page":"2201-2217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II\/III\/IV Clinical Trials"],"prefix":"10.1007","volume":"10","author":[{"given":"Atsunori","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina V.","family":"Shestakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Wilpshaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P. H.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,12]]},"reference":[{"key":"699_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136\u201342. https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02894.x.","journal-title":"Diabet Med"},{"key":"699_CR2","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427\u201334.","journal-title":"Diabetes"},{"key":"699_CR3","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188\u201393. https:\/\/doi.org\/10.1152\/ajprenal.00518.2013.","journal-title":"Am J Physiol Renal Physiol"},{"key":"699_CR4","first-page":"451","volume":"40","author":"JF Mosley","year":"2015","unstructured":"Mosley JF, Smith L, Everton E, Fellner C, Fellner C. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. Pharm Ther. 2015;40:451\u201362.","journal-title":"Pharm Ther"},{"key":"699_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jdiacomp.2012.11.005","volume":"27","author":"VA Fonseca","year":"2013","unstructured":"Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complic. 2013;27:268\u201373.","journal-title":"J Diabetes Complic"},{"key":"699_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/jdi.12156","volume":"5","author":"A Kashiwagi","year":"2014","unstructured":"Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5:382\u201391. https:\/\/doi.org\/10.1111\/jdi.12156.","journal-title":"J Diabetes Investig"},{"key":"699_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.diabres.2018.10.018","volume":"146","author":"MV Shestakova","year":"2018","unstructured":"Shestakova MV, Wilding JPH, Wilpshaar W, Tretter R, Orlova VL, Verbovoy AF. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;146:240\u201350. https:\/\/doi.org\/10.1016\/j.diabres.2018.10.018.","journal-title":"Diabetes Res Clin Pract"},{"key":"699_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/dom.12403","volume":"17","author":"A Kashiwagi","year":"2015","unstructured":"Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes. Diabetes Obes Metab. 2015;17:152\u201360. https:\/\/doi.org\/10.1111\/dom.12403.","journal-title":"Diabetes Obes Metab"},{"key":"699_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13340-014-0164-0","volume":"6","author":"A Kashiwagi","year":"2015","unstructured":"Kashiwagi A, Kazuta K, Takinami Y, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol Int. 2015;6:8\u201318. https:\/\/doi.org\/10.1007\/s13340-014-0164-0.","journal-title":"Diabetol Int"},{"key":"699_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/dom.12038","volume":"15","author":"JPH Wilding","year":"2013","unstructured":"Wilding JPH, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15:403\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"699_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/dom.12331","volume":"17","author":"A Kashiwagi","year":"2015","unstructured":"Kashiwagi A, Kazuta K, Goto K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015;17:304\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"699_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s13340-014-0184-9","volume":"6","author":"A Kashiwagi","year":"2015","unstructured":"Kashiwagi A, Akiyama N, Shiga T, et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetol Int. 2015;6:125\u201338.","journal-title":"Diabetol Int"},{"key":"699_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s13340-014-0182-y","volume":"6","author":"A Kashiwagi","year":"2015","unstructured":"Kashiwagi A, Shiga T, Akiyama N, et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int. 2015;6:104\u201316.","journal-title":"Diabetol Int"},{"key":"699_CR14","first-page":"1","volume":"2018","author":"H Ishihara","year":"2018","unstructured":"Ishihara H, Yamaguchi S, Nakao I, Asahina S, Sakatani T. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study. Diabetol Int. 2018;2018:1\u201314.","journal-title":"Diabetol Int"},{"key":"699_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/jdi.12422","volume":"7","author":"C-H Lu","year":"2016","unstructured":"Lu C-H, Min KW, Chuang L-M, Kokubo S, Yoshida S, Cha B-S. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig. 2016;7:366\u201373. https:\/\/doi.org\/10.1111\/jdi.12422.","journal-title":"J Diabetes Investig"},{"key":"699_CR16","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/dom.13394","volume":"20","author":"K-A Han","year":"2018","unstructured":"Han K-A, Chon S, Chung CH, et al. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial. Diabetes Obes Metab. 2018;20:2408\u201315. https:\/\/doi.org\/10.1111\/dom.13394.","journal-title":"Diabetes Obes Metab"},{"key":"699_CR17","doi-asserted-by":"publisher","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","volume":"11","author":"H Storgaard","year":"2016","unstructured":"Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016;11:e0166125. https:\/\/doi.org\/10.1371\/journal.pone.0166125.","journal-title":"PLoS One"},{"key":"699_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s13340-016-0283-x","volume":"8","author":"A Kashiwagi","year":"2017","unstructured":"Kashiwagi A, Yoshida S, Kawamuki K, et al. Effects of ipragliflozin, a selective sodium\u2013glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetol Int. 2017;8:76\u201386. https:\/\/doi.org\/10.1007\/s13340-016-0283-x.","journal-title":"Diabetol Int"},{"key":"699_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4093\/dmj.2017.41.2.135","volume":"41","author":"K-W Min","year":"2017","unstructured":"Min K-W, Ku BJ, Lee J-H, et al. Addition of ipragliflozin to metformin treatment in Korean patients with type 2 diabetes mellitus: subgroup analysis of a phase 3 trial. Diabetes Metab J. 2017;41:135. https:\/\/doi.org\/10.4093\/dmj.2017.41.2.135.","journal-title":"Diabetes Metab J"},{"key":"699_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","volume":"8","author":"RV Oliva","year":"2014","unstructured":"Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330\u20139. https:\/\/doi.org\/10.1016\/j.jash.2014.02.003.","journal-title":"J Am Soc Hypertens"},{"key":"699_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420\u20138. https:\/\/doi.org\/10.2337\/dc14-1096.","journal-title":"Diabetes Care"},{"key":"699_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1507\/endocrj.EJ17-0491","volume":"65","author":"A Kashiwagi","year":"2018","unstructured":"Kashiwagi A, Sakatani T, Nakamura I, et al. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials. Endocr J. 2018;65:693\u2013705. https:\/\/doi.org\/10.1507\/endocrj.EJ17-0491.","journal-title":"Endocr J"},{"key":"699_CR23","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"699_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"key":"699_CR25","doi-asserted-by":"publisher","first-page":"NEJMoa1811744","DOI":"10.1056\/nejmoa1811744","volume":"2019","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;2019:NEJMoa1811744. https:\/\/doi.org\/10.1056\/nejmoa1811744.","journal-title":"N Engl J Med"},{"key":"699_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"699_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X.","journal-title":"Lancet"},{"key":"699_CR28","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/dom.13679","volume":"21","author":"K Kaku","year":"2019","unstructured":"Kaku K, Isaka H, Toyoshima J, Sakatani T. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: a phase 2, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019;21:1445\u201354. https:\/\/doi.org\/10.1111\/dom.13679.","journal-title":"Diabetes Obes Metab"},{"key":"699_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24\u00a0week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:864\u201376. https:\/\/doi.org\/10.1016\/S2213-8587(17)30308-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"699_CR30","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41:2560\u20139. https:\/\/doi.org\/10.2337\/dc18-1749.","journal-title":"Diabetes Care"},{"key":"699_CR31","doi-asserted-by":"publisher","first-page":"dom.13807","DOI":"10.1111\/dom.13807","volume":"2019","author":"K Kaku","year":"2019","unstructured":"Kaku K, Isaka H, Sakatani T, Toyoshima J. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial. Diabetes Obes Metab. 2019;2019:dom.13807. https:\/\/doi.org\/10.1111\/dom.13807.","journal-title":"Diabetes Obes Metab"},{"key":"699_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","volume":"130","author":"S Filippas-Ntekouan","year":"2018","unstructured":"Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130:72\u201382. https:\/\/doi.org\/10.1080\/00325481.2018.1394152.","journal-title":"Postgrad Med"},{"key":"699_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","volume":"140","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Wu JH, Wong MG, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes\u2014a systematic review. Diabetes Res Clin Pract. 2018;140:118\u201328. https:\/\/doi.org\/10.1016\/j.diabres.2018.03.027.","journal-title":"Diabetes Res Clin Pract"},{"key":"699_CR34","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","volume":"60","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017;60:1385\u20139. https:\/\/doi.org\/10.1007\/s00125-017-4301-8.","journal-title":"Diabetologia"},{"key":"699_CR35","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","volume":"60","author":"H Tang","year":"2017","unstructured":"Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60:1862\u201372. https:\/\/doi.org\/10.1007\/s00125-017-4370-8.","journal-title":"Diabetologia"},{"key":"699_CR36","unstructured":"Food and Drug Administration. FDA briefing document, NDA 202293 Dapagliflozin tablets, 5 and 10\u00a0mg. Advisory Committee Meeting. 2013."},{"key":"699_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157\u201366. https:\/\/doi.org\/10.1210\/jc.2015-3167.","journal-title":"J Clin Endocrinol Metab"},{"key":"699_CR38","unstructured":"Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Safety Announcement 2018. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm617360.htm. Accessed 14 Jan 2019."},{"key":"699_CR39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","volume":"14","author":"D Yabe","year":"2015","unstructured":"Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14:795\u2013800. https:\/\/doi.org\/10.1517\/14740338.2015.1034105.","journal-title":"Expert Opin Drug Saf"},{"key":"699_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1574886311666160405110515","volume":"13","author":"P Vasapollo","year":"2018","unstructured":"Vasapollo P, Cione E, Luciani F, Gallelli L. Generalized intense pruritus during canagliflozin treatment: is it an adverse drug reaction? Curr Drug Saf. 2018;13:38\u201340. https:\/\/doi.org\/10.2174\/1574886311666160405110515.","journal-title":"Curr Drug Saf"},{"key":"699_CR41","doi-asserted-by":"publisher","first-page":"937","DOI":"10.7150\/ijms.22224","volume":"15","author":"T Sakaeda","year":"2018","unstructured":"Sakaeda T, Kobuchi S, Yoshioka R, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018;15:937\u201343. https:\/\/doi.org\/10.7150\/ijms.22224.","journal-title":"Int J Med Sci"},{"key":"699_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40261-016-0438-3","volume":"36","author":"A Mellander","year":"2016","unstructured":"Mellander A, Billger M, Johnsson E, Tr\u00e4ff AK, Yoshida S, Johnsson K. Hypersensitivity events, including potentially hypersensitivity-related skin events, with dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis. Clin Drug Investig. 2016;36:925\u201333. https:\/\/doi.org\/10.1007\/s40261-016-0438-3.","journal-title":"Clin Drug Investig"},{"key":"699_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40265-014-0204-x","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs. 2014;74:611\u20137. https:\/\/doi.org\/10.1007\/s40265-014-0204-x.","journal-title":"Drugs"},{"key":"699_CR44","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1080\/14656566.2016.1219341","volume":"17","author":"K Yokote","year":"2016","unstructured":"Yokote K, Terauchi Y, Nakamura I, Sugamori H. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17:1995\u20132003. https:\/\/doi.org\/10.1080\/14656566.2016.1219341.","journal-title":"Expert Opin Pharmacother"},{"key":"699_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14656566.2017.1408792","volume":"19","author":"I Nakamura","year":"2018","unstructured":"Nakamura I, Maegawa H, Tobe K, Tabuchi H, Uno S. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opin Pharmacother. 2018;19:189\u2013201. https:\/\/doi.org\/10.1080\/14656566.2017.1408792.","journal-title":"Expert Opin Pharmacother"},{"key":"699_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-0895-1","author":"I Nakamura","year":"2019","unstructured":"Nakamura I, Maegawa H, Tobe K, Uno S. Safety and effectiveness of ipragliflozin for type 2 diabetes in japan: 12-month interim results of the STELLA-LONG TERM post-marketing surveillance study. Adv Ther. 2019. https:\/\/doi.org\/10.1007\/s12325-019-0895-1.","journal-title":"Adv Ther"},{"key":"699_CR47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. Ann Intern Med. 2013;159:262. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007.","journal-title":"Ann Intern Med"},{"key":"699_CR48","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I\u2013III clinical trials. Adv Ther. 2017;34:1707\u201326. https:\/\/doi.org\/10.1007\/s12325-017-0573-0.","journal-title":"Adv Ther"},{"key":"699_CR49","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/dom.13124","volume":"20","author":"S Jabbour","year":"2018","unstructured":"Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials. Diabetes Obes Metab. 2018;20:620\u20138. https:\/\/doi.org\/10.1111\/dom.13124.","journal-title":"Diabetes Obes Metab"},{"key":"699_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/03007995.2016.1271780","volume":"33","author":"R Qiu","year":"2017","unstructured":"Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017;33:553\u201362. https:\/\/doi.org\/10.1080\/03007995.2016.1271780.","journal-title":"Curr Med Res Opin"},{"key":"699_CR51","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7:2824. https:\/\/doi.org\/10.1038\/s41598-017-02733-w.","journal-title":"Sci Rep"},{"key":"699_CR52","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM446954.%0Apdf. Accessed 14 Jan 2019."},{"key":"699_CR53","unstructured":"European Medicines Agency. SGLT2 Inhibitors. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes 2016. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/sglt2-inhibitors. Accessed 14 Jan 14 2019."},{"key":"699_CR54","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/VHRM.S111991","volume":"12","author":"JW Reed","year":"2016","unstructured":"Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393\u2013405. https:\/\/doi.org\/10.2147\/VHRM.S111991.","journal-title":"Vasc Health Risk Manag"},{"key":"699_CR55","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71:2628\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.009.","journal-title":"J Am Coll Cardiol"},{"key":"699_CR56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","volume":"4","author":"JHY Wu","year":"2016","unstructured":"Wu JHY, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(16)00052-8.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-00699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-019-00699-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-00699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:53:23Z","timestamp":1724414003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-019-00699-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s13300-019-00699-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,12]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}